CRX Cyprotex

 

TIDMCRX 
 
 
Cyprotex PLC 
21 April 2010 
 
? 
21 April 2010 
 
Cyprotex PLC ("Cyprotex" or the Company") 
 
Cyprotex Discovery Receives French Research Tax Credit Accreditation 
 
Cyprotex (AIM:CRX), the drug discovery technology and information company, is 
pleased to announce that it has received French research tax credit approval for 
years 2009 through to 2011. 
 
The French Ministry of Research (Ministère de l'Enseignement Supérieur et de la 
Recherche) has granted the French R&D tax credit ("Crédit d'Impôt Recherche", 
CIR) accreditation to Cyprotex as of March 2010.  This initiative allows 
eligible French pharmaceutical, biotech and agricultural companies subject to 
corporate tax in France, the ability to claim significant tax relief on costs 
generated in R&D requirements that are outsourced to Cyprotex Discovery. 
 
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: 'We are 
delighted to receive this recognition and approval from the French Ministry of 
Research which will provide greater opportunities to support our current client 
base and allow for improved collaborations with future French clients.' 
 
Additional information on the French research tax credit system is available 
from the Ministère de l'Enseignement Supérieur et de la Recherche site - 
http://www.enseignementsup-recherche.gouv.fr/ 
 
 For further information: 
 
Cyprotex PLC 
Dr. Anthony Baxter, Chief Executive Officer 
Tel: +44 1625 505 100 
a.baxter@cyprotex.com 
www.cyprotex.com 
 
Execution Noble & Company Limited 
John Llewellyn-Lloyd 
Sam Reynolds 
Tel: 020 7456 9191 
 
Public Relations 
Financial Dynamics 
Ben Brewerton 
Ben Atwell 
Mo Noonan 
Tel: 020 7831 3113 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAKKKDPABKDOQB 
 

Cyprotex (LSE:CRX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2023 to Apr 2024